To read our full disclaimer, click here.
Every so often a position resolves the easy way.
On 29 July, MIMEDX Group agreed to acquire Sanara MedTech.
We initiated coverage on 6 January at $24.00. The deal values Sanara at $35.00 a share.
That is +45.8% in a little under seven months.
The path there was not a straight line.
In March, after an ugly Q4 print, the stock was $18, down 25% from initiation. I wrote an update at that price arguing the business had got cheaper for the wrong reasons and the thesis was intact.
From $18, the deal price is 94.4% higher, in four months.
To mark the result, I’m giving away one annual subscription at 50% off. First person to redeem it gets it.
The Deal
MIMEDX is paying $33.00 in cash plus 0.4735 MIMEDX shares for each Sanara share. On MIMEDX’s five-day average close of $4.22, that works out to $35.00 per share.
Total enterprise value is roughly $350 million, a 46% premium to Sanara’s 30-day volume-weighted average price as of 28 July.
Both boards approved unanimously. MIMEDX is funding the cash portion from existing cash plus a new $300 million term loan from Hayfin Capital Management, with its existing credit agreement repaid and terminated in full.
Closing is expected by the end of 2026, subject to Sanara shareholder approval and regulatory clearance.
One detail is worth pulling out. The March update ran Sanara at 3x forward sales - the low end of the surgical med-tech peer range - and got to roughly $36 a share.
MIMEDX paid $35.
How It Played Out
The thesis in January was not complicated.
Sanara was a profitable, growing surgical products business. 93% gross margins, 22% revenue growth, trading at about 2.4x EV/Sales while comparable surgical med-tech changed hands at 3-6x.
Management had just done the hard thing, shutting down the loss-making Tissue Health Plus segment to become a clean surgical pure-play. The distributor model was scaling revenue on flat internal headcount: 22% growth on the same 40 field reps they had run for three years.
Sitting on top of that was OsStic, a synthetic injectable bone adhesive with FDA Breakthrough Device Designation, which the market valued at zero.
Then Q4 landed and the stock fell apart.
Revenue grew 5%. Operating income missed by 66%. A noncash impairment hit the P&L. And the debt balance, which the original thesis expected to come down, went up instead - from $30.7 million to $46 million, with interest expense more than doubling to $6.8 million.
The stock went to $18.
The March update argued the headline was hiding the progress.
The 5% growth was a hurricane comp, with Q4 2024 carrying roughly $1.8 million of one-off BIASURGE demand from a saline shortage. Strip it out and Q4 grew 13%. Strip the impairment and operating income grew 28%. The THP wind-down was complete and under budget. A Vizient contract had just opened roughly 1,800 new facilities for the fastest-growing product, close to doubling the addressable base overnight.
The one thing that update would not wave away was the debt. No credit until the April refinancing actually happened.
It never happened. A buyer refinanced the whole company instead.
What the Trade Teaches
The price fell 25%. The business didn’t.
Between the January thesis and the March update the stock lost a quarter of its value. Over the same stretch the business reported full-year revenue crossing $100 million for the first time, up 19%. Gross margin up 200 basis points to 93%. Adjusted EBITDA up 86% to $17 million. Operating cash flow moving from essentially nothing to $6.8 million, or roughly $16 million stripping out the THP wind-down. The distributor network went from 350 partners to over 450, facility customers to over 1,450, and the loss-making segment was shut.
Every operating line moved forward. The share price was the only thing that went backwards.
The work in that window was not deciding whether the stock looked cheap.
It was checking, line by line, whether anything in the thesis had actually broken. In my opinion nothing had.
Optical mess stops mattering the moment a buyer turns up.
What broke the stock in March was a hurricane-inflated prior-year comparison, a noncash impairment charge and a GAAP loss line. All three are screen-level artefacts. None of them changed how much collagen product Sanara sold, what it cost to make, or how many hospitals were buying it.
Four months later MIMEDX paid a 46% premium.
An acquirer normalises the comp, adds back the impairment and refinances the debt onto its own balance sheet, because it is buying the asset rather than the quarterly presentation of it.
Accounting ugliness is a discount available to whoever is willing to look underneath it.
This could have gone the other way, and the debt is the reason.
Debt went from $30.7 million to $46 million during 2025 and interest expense more than doubled to $6.8 million at a 13.5% rate.
The April 2026 refinancing the original thesis assumed would happen never did.
The March update flagged this as the open risk and declined to give credit for a refinancing until it landed.
We never found out how that resolved, because a buyer took the entire balance sheet out.
That is a good outcome arriving from outside the thesis.
Had no buyer turned up and growth come in at the low end of the 13-17% guide, the same balance sheet would have been exactly the problem the March note said it might be.
Leverage is what separates a thesis that is merely slow from one that does permanent damage, and the honest reading here is that the risk was correctly identified and then resolved by luck rather than by anything in the analysis.
Where That Leaves Holders
The stock trades close to, but a shade below, the deal value. That is the usual arbitrage discount for time and completion risk.
A modest spread remains for holders willing to sit through closing and carry the regulatory and shareholder-vote risk. That is a merger-arb decision rather than the idea we underwrote in January, and it is a different game with different skills.
For our purposes the thesis has done its job. The gap we identified has closed. There is no mispricing here left to be right about.
The Bottom Line
Sanara did what we hoped, faster than expected and by a route we did not model.
A profitable, growing, 93%-gross-margin surgical business at half its peer multiple, bought in January, held through a quarter that read far worse than it was, and taken out at $35 in July.
The part I would repeat is watching the operating lines rather than the quote when the stock fell. The part I would not claim credit for is the debt, which was the one thing flagged as most likely to go wrong and which got solved by an acquirer rather than by management.
+45.8% from initiation in January. +94.4% from the March update. Coverage closed.
There will be no further updates on Sanara MedTech.
Remember, I’m giving away one annual subscription at 50% off.
If you want to view all our future healthcare research, now is the time to join.
As always, this is not investment advice. Do your own research, consider your own risk tolerance, and make your own decisions.
Thanks for reading,
Nico
Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Healthcare Stock Ideas. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.